Level D· Scientific groundwork from lab and animal studiesLaboratory StudyPubMed

Persistence of plasmid-mediated expression of transgenes in human mesenchymal stem cells depends primarily on CpG levels of both vector and transgene.

Bruter AV., Kandarakov OF., Belyavsky AV.

Laboratory Study, published in J Gene Med (2018) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
J Gene Med (2018)
Country
England
Reported sample size
—
Source database
PubMed
PMID
29424052
DOI
10.1002/jgm.3009

Abstract (original English)

Gene therapy and cell modification for clinical applications using plasmid vectors are considered to be a safe and promising strategy. One of the major problems with plasmid vector-based constructs is a rapid decline of transgene expression in cells in vitro and in vivo. An important role of CpG motifs or bacterial vector backbone in expression silencing has been suggested. To address the effects of CpG motifs on transgene expression maintenance in stem cells in vitro, we constructed a novel pMBR2 plasmid vector containing 13 CpG motifs only. pMBR2 constructs with CpG-free and CpG-replete firefly luciferase inserts were introduced into cultured human adipose-derived mesenchymal stem (MSCs) by electroporation, and luciferase expression levels were monitored for 3 weeks. The pMBR2 vector with CpG-free luciferase insert demonstrated the highest persistence of expression, whereas the wild-type luciferase insert containing 97 CpG motifs demonstrated lower expression maintenance in the same vector. In comparison, the same inserts in the CpG-replete pCDNA3 vector demonstrated significantly lower expression levels and only a minimal persistence of expression. β-galactosidase and enhanced green fluorescent protein genes inserted into pMBR2 vector also demonstrated higher expression levels and better maintenance compared to the same genes in pCDNA3 vector. The persistence of plasmid vect

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
CpG IslandsGene Expression RegulationGenetic TherapyGenetic VectorsGreen Fluorescent ProteinsHumansMesenchymal Stem CellsPlasmidsTransgenes

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.